Dannielle Appelhans - 31 Jan 2022 Form 4 Insider Report for Rubius Therapeutics, Inc.

Role
Chief Operating Officer
Signature
/s/ Joanne M. Protano, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
31 Jan 2022
Net transactions value
$0
Form type
4
Filing time
01 Feb 2022, 20:19:53 UTC
Previous filing
01 Sep 2021
Next filing
19 Jul 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RUBY Stock Option (Right to Buy) Award $0 +125,000 $0.000000 125,000 31 Jan 2022 Common Stock 125,000 $6.75 Direct F1
transaction RUBY Restricted Stock Units Award $0 +30,000 $0.000000 30,000 31 Jan 2022 Common Stock 30,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option shall vest on January 31, 2023, then in 12 equal quarterly installments thereafter.
F2 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3 The shares underlying the restricted stock units vest in four equal annual installments beginning on January 31, 2023.